Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 20, 2006. The filing discloses the creation of a direct financial obligation under a previously established Master Security Agreement with Oxford Finance Corporation.
Key Financial Metrics
The filing details a new borrowing event rather than periodic financial performance metrics such as revenue or profit.
- Total Borrowing Amount: Approximately $2.3 million.
- Loan Component 1: Approximately $2.1 million at a fixed interest rate of 10.37%, repayable in 48 monthly installments.
- Loan Component 2: Approximately $0.2 million at a fixed interest rate of 10.35%, repayable in 36 monthly installments.
- Repayment Start Date: June 20, 2006.
Material Changes
The material change reported is the execution of a drawdown under the Master Security Agreement entered into on March 31, 2006. This transaction increases the company's debt obligations and creates a new liability on the balance sheet.
Outlook, Risks, and Management Commentary
Use of Proceeds: The funds are designated to partially fund the expansion of office and laboratory space at the company's Cambridge, MA facility, as well as the purchase of additional computer and laboratory equipment.
Risks and Contingencies: The filing does not explicitly list new risks beyond the standard obligation to repay the principal and interest. The filing text does not provide a clear value for total outstanding debt prior to this transaction or the company's current liquidity position.
Investor Verification Checklist
- Verify the total outstanding debt balance of Alnylam Pharmaceuticals, Inc. following this $2.3 million drawdown.
- Confirm the company's cash flow sufficiency to meet the new monthly principal and interest obligations starting June 20, 2006.
- Review the full terms of the Master Security Agreement dated March 31, 2006, for any covenants or default triggers.
- Assess the progress and capital requirements of the Cambridge facility expansion project.